ABSTRACT
ObjectivesCOVID-19 reinfection cases are evidence of antibody waning in recovered individuals. Previous studies had reported cases of COVID-19 reinfection both in hospital-based and community-based data. However, limited studies reported COVID-19 reinfection in large community-based data. The present study aimed to provide the incidence of COVID-19 reinfection based on secondary data in the U.S. Study designCross-sectional study MethodsA cross-sectional study was conducted using secondary data provided by COVID-19 Research Database, i.e., Healthjump. Reinfection were defined as diagnosed COVID-19 (U07.1= confirmed virus identified) twice with [≥]90 days interval between diagnosis. Age, gender, and region data were also explored. A Chi-square test continued by a binary logistic regression was conducted to determine the association between parameters. Data collecting and processing were done in the Amazon workspace. ResultsThe study revealed 3,778 reinfection cases of 116,932 COVID-19 infected cases (3.23%). Reinfection cases were more common in females (3.35%) than males (3.23%). Elderly subjects were the highest incidence (5.13%), followed by adult (4.14%), young adults (2.35%), and children (1.09%). Proportion in the region of living northeast was the highest (3.68%), compared to the south (3.49%), west (2.59%), and midwest (2.48%). ConclusionThe incidence of COVID-19 reinfection was 3.23%, suggesting our concern with COVID-19 management and future research to understand COVID-19 reinfection better. The incident is more likely to occur in female and elderly patients.
ABSTRACT
BackgroundPrevious studies reported recurrent SARS-CoV-2 RNA positivity in individuals who had recovered from COVID-19 infections. However, little is known regarding the systematic review of recurrent SARS-CoV-2 RNA positivity. The current study conducted a systematic review and meta-analysis, aimed to estimate the incidence of recurrent SARS-CoV-2 RNA positivity after recovery from COVID-19 and to determine the factors associated with recurrent positivity. MethodsWe searched the PubMed, MedRxiv, BioRxiv, the Cochrane Library, ClinicalTrials.gov, and the World Health Organization International Clinical Trials Registry for studies published to June 12, 2020. Studies were reviewed to determine the risk of bias. A random-effects model was used to pool results. Heterogeneity was assessed using I2. ResultsFourteen studies of 2,568 individuals were included. The incidence of recurrent SARS-CoV-2 positivity was 14.81% (95% confidence interval [CI]: 11.44-18.19%). The pooled estimate of the interval from disease onset to recurrence was 35.44 days (95% CI: 32.65-38.24 days), and from the last negative to recurrent positive result was 9.76 days (95% CI: 7.31-12.22 days). Patients with younger age (mean difference [MD]=-2.27, 95% CI: -2.95 to -1.80) and a longer initial illness (MD=8.24 days; 95% CI: 7.54 - 8.95; I2=98.9%) were more likely to experience recurrent SARS-CoV-2 positivity, while patients with diabetes (RR=0.52; 95% CI: 0.30-0.90; I2=53%), severe disease (RR=0.54; 95% CI: 0.35-0.84; I2=70%), and a low lymphocyte count (RR=0.58; 95% CI: 0.39 - 0.86; I2=48%) were less likely to experience recurrent SARS-CoV-2 positivity. ConclusionsThe incidence of recurrent SARS-CoV-2 positivity was 14.81%. The estimated interval from disease onset to repeat positivity was 35.44 days, and the estimated interval from the last negative result to recurrent positive result duration was 9.76 days.
ABSTRACT
@#Diabetes mellitus (DM) is a well-known risk factor for tuberculosis (TB). Prevalence of TB among DM patients ranged from 1.7 % to 36 %. Limited information has been reported regarding TB among DM patients in Indonesia. This case-control study aimed to investigate prevalence and related factors of pulmonary TB among DM patients in Dr. Kariadi General Hospital. Cases of pulmonary TB were defined by a positive acid-fast bacilli smear or molecular rapid test and thorax x-ray. Data were presented as frequency and percentage comparing the case and control group. Chi-square continued by Binary logistic regression analyses were done to determine the relationship between the parameters and TB status performed by the SPSS 16. Prevalence of 8.02% or 72 patients were diagnosed as having pulmonary TB from 898 registered patients with DM. Of the 72 TB patients, 30 completed the data as case group, and 45 DM patients without TB determined as a control group. Comparison between the case and control group study found differences in household contact (63.3 % and 4.4 %, respectively), random plasma glucose (76.7 % and 33.3 %), duration of DM (40 % and 71 %), and treatment compliance (30 % and 68.9 %). The final model in Binary logistic regression involved household contact, random plasma glucose level, and treatment compliance. The prevalence of pulmonary TB among DM patients in Dr. Kariadi General Hospital was 8.02%. Risk factors that were associated with this occurrence were: household contact, high random plasma glucose level, and poor treatment compliance.
